To determine whether rapid emergence of Salmonella enterica serovar Infantis in Israel resulted from an increase in different biotypes or spread of 1 clone, we characterized 87 serovar Infantis isolates on the genotypic and phenotypic levels. The emerging strain comprised 1 genetic clone with a distinct pulsed-field gel electrophoresis profile and a common antimicrobial drug resistance pattern.

Non-typhoid Salmonella enterica (NTS) is a common cause of foodborne illnesses worldwide. In industrialized countries, S. enterica serovars Enteritidis and Typhimurium are responsible for most NTS infections (1). In Israel, the distribution of NTS infections differs from the global epidemiology for NTS by having a larger representation of serogroups C1 and C2 (serovars Virchow, Hadar, and Infantis) in addition to serovars Enteritidis and Typhimurium (2,3).

Analysis of annual trends of NTS infections in Israel during 1995–2009 shows a steady decrease in the incidence of these infections, from 86.9 cases/100,000 persons in 1995 to 31.4/100,000 in 2005. During this period, the predominant serovars were Enteritidis, Typhimurium, Virchow, and Hadar, followed by Infantis. Since 2006, annual incidence of NTS has started to increase, rising to 44.0 cases/100,000 persons in 2009. This trend coincided with a sharp increase in incidence of serovar. Infantis from 1.2 cases/100,000 persons in 2001 to 14.7/100,000 in 2009, a 12-fold rise (Figure 1, panel A). The proportion of serovar Infantis increased from <10% of NTS in 1995–2005 to 34% in 2009 (Figure 1, panel B). Furthermore, this steep increase in serovar Infantis from clinical (human) sources correlated with an elevated frequency of serovar Infantis in poultry (Figure 1, panel C).
from poultry that became apparent after 2006. Serovar Infantis became the predominant serotype in poultry during 2007–2009, while the prevalences of serovars Enteritidis, Typhimurium, Virchow, Bredeney, Newport, and Paratyphi B var. Java decreased (Figure 1, panel C).

The Study

Molecular analysis was used to study whether the rapid emergence of *S. enterica* ser. Infantis resulted from a general increase in different biotypes or a successful spread of 1 clone. Seventy-one randomly selected isolates of *S. enterica* ser. Infantis identified in Israel during 2007–2009 (21 human sources, 28 poultry sources, and 22 food sources) and 16 historical strains isolated during 1970–2005 (12 human sources, 2 poultry sources, and 2 food sources) were subjected to pulsed-field gel electrophoresis (PFGE). Macrorestriction with the XbaI enzyme discriminated the isolates into 23 distinct profiles (pulsotypes), designated I1–I23. Although the historical isolates showed high diversity in their PFGE patterns, most (58/71, 82%) recent (2007–2009) isolates were homogeneous and showed an indistinguishable PFGE profile (pulsotype I1), which was not found among the historical isolates (Figure 2; online Appendix Table, www.cdc.gov/EID/content/16/11/1754-appT.htm). These results indicate that most of the emerging isolates belong to 1 genetic clone that probably started to spread in Israel sometime during 2005–2007. Furthermore, comparison of the I1 pulsotype with other PFGE profiles through PulseNet (www.cdc.gov/pulsenet/) and PulseNet Europe (www.pulsenetinternational.org/networks/europe.asp) indicated a pattern not reported elsewhere, suggesting the emerging clone is endemic to Israel.

To further characterize the isolates, we performed susceptibility tests to 16 antimicrobial compounds. Overall, resistance to 11 antimicrobial agents was detected (Table; online Appendix Table). Two clear differences were found between the strains isolated before and after 2007. First, 6/16 (38%) of the historical strains were sensitive to all tested antimicrobial agents and 5/16 (31%) were resistant to only 1 (nitrofurantoin), none of the 2007–2009 isolates were sensitive to all of the tested antimicrobial agents. Most (68/71, 96%) of the recent isolates were resistant to ≥3 antimicrobial agents, which suggests a process of resistance acquisition over time. Second, whereas isolates from 1970–2005 did not share any obvious resistance pattern, most (66/71, 93%) of the 2007–2009 strains showed a combined resistance pattern to nalidixic acid, nitrofurantoin, and tetracycline with or without additional resistance to trimethoprim/sulfamethoxazole (Table). The convergence of the recent serovar Infantis clones to a dominant resistance pattern is consistent with their common PFGE profile and shows that they share high similarity on phenotypic and genotypic levels.

Next, we characterized the molecular mechanisms responsible for the common antimicrobial drug–resistance phenotype. In bacteria, an efficient means of acquisition and dissemination of resistance genes is through mobile genetic elements such as plasmids, transposons, or integrons (5). Plasmid analysis for 15 emerging (2007–2009) and 7 historical (1970–2005) randomly selected isolates demonstrated that all possessed 1 large plasmid of ≥100 kb. To

![Figure 2. Pulsed-field gel electrophoresis (PFGE) patterns of Salmonella enterica serovar Infantis isolates from clinical, food, and poultry sources isolated in Israel, 1970–2009, showing a high degree of clonality. Isolate number, year of isolation, and source are indicated. Bracket indicates I1 pulsotype pattern. Macrodigestion performed using XbaI restriction enzyme and genetic similarity (in %) was based on dice coefficients. PFGE was conducted according to the standardized Salmonella protocol Centers for Disease Prevention and Control PulseNet as described (4) by using S. enterica ser. Braenderup H9812 strain as a molecular size standard. Because of space limitations, only 34/58 pulsotype I1 clones are shown. A complete list is provided in the online Appendix Table (www.cdc.gov/EID/content/16/11/1754-appT.htm)
identify antimicrobial drug resistance genes that are possibly encoded on this plasmid, mating experiments were conducted with a plasmid-free, rifampin-resistant *Escherichia coli* J5–3 strain and recent *S. enterica* ser. Infantis isolates harboring tetracycline, nalidixic acid, and nitrofurantoin resistance genes. Conjugation experiments showed the obtained *E. coli* transconjugants received the large (≈100-kb) plasmid and acquired the tetracycline resistance phenotype but remained susceptible to nalidixic acid and nitrofurantoin. We concluded the tetracycline resistance gene(s) is encoded on the conjugative plasmid. Molecular analysis by PCR showed the tetA gene encoded within the Tn1721 transposon in 6 of 6 randomly selected emerging isolates but in only 1 of 5 older historical strains.

We examined class 1 integrons using PCR primers designed to amplify the variable region of class 1 integrons. All 6 recent isolates bore 1 integron with a variable region of ≈1 kb. Sequencing of the resulting amplicon showed the dfrA1 gene cassette conferring resistance to trimethoprim–sulfamethoxazole followed by the orfC gene of unknown function. In contrast, 3/5 historical isolates did not possess any integron, and 2/5 contained a disparate integron with a variable region of ≈1.3 kb. Sequencing analysis indicated a different cassette encoded by the aminoglycoside adenyltransferase aadA1 gene conferring resistance to spectinomycin and streptomycin.

Resistance to quinolones is often associated with point mutations in the quinolone-resistance determining region of the gyrA gene (6). To examine this possibility, we determined the gyrA sequence from 6 recent naladixic acid–resistant and 4 naladixic acid–sensitive isolates. All resistant clones showed the same nucleotide substitution from guanine to thymine at position 259 (G259T) in the gyrA gene, resulting in the exchange of asparagine in position 87 to tyrosine (Asp87Tyr) in the quinolone resistance–determining region domain. No mutations were found in the gyrA sequence of the naladixic acid–sensitive isolates, suggesting that the Asp87Tyr point mutation is responsible for the observed naladixic acid–resistance phenotype.

**Conclusions**

It is likely that environmental selective pressure caused by use of antimicrobial drugs has led to the distribution of appropriate resistant genes. Nitrofurans and sulfonamides, for example, have been widely used to treat infections and promote growth of livestock (7). Because the emerging clone was dominant in all levels of the food chain, including broiler chickens, it is possible that the emerging clone was originally introduced from a poultry source. Recent studies from other countries identified healthy poultry as a potential reservoir of *S. enterica* ser. Infantis (8–10).

Molecular and phenotypic characterization of recent *S. enterica* ser. Infantis isolates from different sources and regions in Israel showed high homogeneity of emerging isolates that differ genetically and phenotypically from previously isolated strains. We showed that the emerging clone is multidrug resistant and is characterized by a large conjugative plasmid harboring the Tn1721 transposon and tetA gene, which provides reduced susceptibility to tetracyclines. Additional characteristics include a class 1 integron containing the dfrA1 cassette, a gyrA mutation that mediates nalidixic acid resistance and furthers resistance to nitrofurantoin. Our results suggest the recent emergence of serovar Infantis is an outcome of a clonal expansion and establishment of a specific biotype that took place during a
relatively short period. Virulence mechanisms contributing to this phenomenon are the subject of an ongoing study.

Acknowledgments

We thank Noemi Nógrády for providing the Escherichia coli J5-3 Rif\textsuperscript{R} strain.

This study was supported by funding from the European Community’s Seventh Framework Program (FP7/2007-2013) under grant agreement no. 249241 and from the Chief Scientist of the Israeli Ministry of Health under grant agreement no. 3-00000-6356.

Dr Gal-Mor is a molecular microbiologist and head of the Infectious Diseases Research Laboratory at the Sheba Medical Center, Tel-Hashomer, Israel. His primary research interests include microbial pathogenicity and Salmonella virulence and epidemiology.

References


Address for correspondence: Ohad Gal-Mor, The Infectious Diseases Research Laboratory, Sheba Medical Center, Tel-Hashomer 52621, Israel; email: ohad.gal-mor@sheba.health.gov.il

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.